Pan-cancer multi-omics profiling of SRPK1 identifies tumour-specific associations with prognosis and predicted chemotherapy response in breast, colon and prostate cancer
- 1Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, United Kingdom
Abstract
Purpose: Serine/arginine-rich protein kinase 1 (SRPK1), a regulator of splicing-factor activity and alternative splicing, has been implicated in cancer progression and therapy resistance. However, the tumour-specific expression landscape and clinical relevance of SRPK1 across human cancers remain incompletely defined. This study aimed to investigate SRPK1 expression, prognostic relevance, and associations with predicted chemotherapy response through pan-cancer multi-omics profiling, with a focused evaluation in breast, colon, and prostate cancer.
Methods: Public transcriptomic, proteomic, immunohistochemical, survival, functional network and pharmacogenomic datasets were interrogated, including TCGA, GEPIA2, CPTAC/UALCAN, the Human Protein Atlas, GeneMANIA, STRING, GSCA and CPADS. SRPK1 mRNA and protein expression, survival associations, SRPK1-related splicing networks, SRPK1–SRSF1 co-expression and predicted drug-response associations were assessed in breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD) and prostate adenocarcinoma (PRAD) cohorts.
Results: SRPK1 displayed heterogeneous expression across TCGA tumour types, supporting tumour-specific dysregulation. SRPK1 mRNA and protein levels were increased in BRCA and COAD, whereas in PRAD, expression changes were more dataset-dependent. Survival analyses revealed cancer-type-dependent prognostic associations: high SRPK1 expression was associated with poorer outcomes in BRCA, whereas low SRPK1 expression was associated with poorer outcomes in COAD. SRPK1 was positively co-expressed with SRSF1 and mapped to splicing-related interaction networks. Pharmacogenomic analyses further linked SRPK1 expression to drug-sensitivity variation in cancer cell lines and to tumour-type-specific predicted chemotherapy response, including cisplatin in COAD and docetaxel in PRAD.
Conclusion: These findings identify SRPK1 as a context-dependent molecular candidate associated with prognosis and predicted chemotherapy response in breast, colon and prostate cancer, supporting future experimental validation of SRPK1-linked splicing pathways in tumour-specific chemoresistance.
Related
- Longitudinal single-cell analysis identifies a chemotherapy-suppressed proliferative program associated with adverse prognosis in neuroblastoma
- Organ-Differentiated Metabolomic Profiling Reveals Putative Associations Between Predicted Bioactivity and Database-Annotated Flavor in Medicinal–Edible Talinum paniculatum (Jacq.) Gaertn
- Structural Modeling Identifies a Conserved ADAR1 dsRBDIII Motif Predicted to Interact with PKR at Thr451
- Evolution-Informed Viroinformatics Identifies Conserved Immune Targets with Predicted Lower Mutational Vulnerability Across Betacoronaviruses.
- CausalCellInfer: Prioritizing Cell-Type-Specific Disease Associations From Genetically Predicted Transcriptomes in Biobank Cohorts.
BibTeX
@article{duzgun2026pancancer,
title = {{Pan-cancer multi-omics profiling of SRPK1 identifies tumour-specific associations with prognosis and predicted chemotherapy response in breast, colon and prostate cancer}},
author = {Duygu Duzgun and Sebastian Oltean},
journal = {Frontiers in Bioinformatics},
year = {2026},
month = oct,
doi = {10.3389/fbinf.2026.1925354},
url = {https://doi.org/10.3389/fbinf.2026.1925354},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pan-cancer multi-omics profiling of SRPK1 identifies tumour-specific associations with prognosis and predicted chemotherapy response in breast, colon and prostate cancer
AU - Duygu Duzgun
AU - Sebastian Oltean
PY - 2026
DA - 2026/10/21
JO - Frontiers in Bioinformatics
DO - 10.3389/fbinf.2026.1925354
UR - https://doi.org/10.3389/fbinf.2026.1925354
AB - Purpose: Serine/arginine-rich protein kinase 1 (SRPK1), a regulator of splicing-factor activity and alternative splicing, has been implicated in cancer progression and therapy resistance. However, the tumour-specific expression landscape and clinical relevance of SRPK1 across human cancers remain incompletely defined. This study aimed to investigate SRPK1 expression, prognostic relevance, and associations with predicted chemotherapy response through pan-cancer multi-omics profiling, with a focused evaluation in breast, colon, and prostate cancer. Methods: Public transcriptomic, proteomic, immunohistochemical, survival, functional network and pharmacogenomic datasets were interrogated, including TCGA, GEPIA2, CPTAC/UALCAN, the Human Protein Atlas, GeneMANIA, STRING, GSCA and CPADS. SRPK1 mRNA and protein expression, survival associations, SRPK1-related splicing networks, SRPK1–SRSF1 co-expression and predicted drug-response associations were assessed in breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD) and prostate adenocarcinoma (PRAD) cohorts. Results: SRPK1 displayed heterogeneous expression across TCGA tumour types, supporting tumour-specific dysregulation. SRPK1 mRNA and protein levels were increased in BRCA and COAD, whereas in PRAD, expression changes were more dataset-dependent. Survival analyses revealed cancer-type-dependent prognostic associations: high SRPK1 expression was associated with poorer outcomes in BRCA, whereas low SRPK1 expression was associated with poorer outcomes in COAD. SRPK1 was positively co-expressed with SRSF1 and mapped to splicing-related interaction networks. Pharmacogenomic analyses further linked SRPK1 expression to drug-sensitivity variation in cancer cell lines and to tumour-type-specific predicted chemotherapy response, including cisplatin in COAD and docetaxel in PRAD. Conclusion: These findings identify SRPK1 as a context-dependent molecular candidate associated with prognosis and predicted chemotherapy response in breast, colon and prostate cancer, supporting future experimental validation of SRPK1-linked splicing pathways in tumour-specific chemoresistance.
SN - 2673-7647
ER -